Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Follicular Lymphomas Clinical Trial

Official title:
Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas

Status Completed

Clinical Trial Summary

Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019. 12 total patients will be enrolled. Safety of pembrolizumab (primary endpoint) will be determined using a Bayesian monitoring rule for treatment-related adverse events causing drug discontinuation. Secondary efficacy endpoints include overall response rate and progression-free survival.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02650999
Study type	Interventional
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 2016
Completion date	June 12, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01474681` - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT00991211` - Bendamustine Plus Rituximab Versus CHOP Plus Rituximab	Phase 3
Active, not recruiting	`NCT00877214` - Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas	Phase 3